Seems like a calling card was left from my "friends" at ZIP, but here I go again, expanding the details because apparently, it's necessary
@primaus72 I completely agree with you. Regeneron, with its US$9.8 billion locked away in its "petty cash" draw it can easily afford to acquire Opthea if P3 is successful.
So, my shares are available US$9.7 is AUD$14B and with 1.23B shares that is $11.82 per share. While this may seem fanciful, realistically, Regeneron will absolutely have their back against the wall. Acquiring OPT would be incredibly profitable over the following decade—even if they have to raid the petty cash draw.
Whilst we don't talk about it if P3 is a marginal ( 1-2 letters, or just for some special conditions) Regeneron could pick OPT for a song and a dance (10cents/share) just to stop it being picked up by Roache.
- Forums
- ASX - By Stock
- OPT
- Ann: Security Class Reinstatement to Quotation- OPTOB
OPT
opthea limited
Add to My Watchlist
0.00%
!
60.0¢

Ann: Security Class Reinstatement to Quotation- OPTOB, page-528
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
OPT (ASX) Chart |
Day chart unavailable
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online